Familiar
Familiar translates proven human medicines into novel therapeutics for companion animals, addressing the gap between human drug innovation and veterinary treatment options. The company's pipeline includes 13 active drug development programs spanning cancers, autoimmune conditions, and metabolic diseases, with lead candidate FAM-010 currently in a clinical study for dogs with hemangiosarcoma.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
- Pet Technology
- Medical Devices
- Hardware
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Pets develop many of the same cancers, autoimmune conditions, and metabolic diseases that affect humans, driven by the same underlying biology. However, while the FDA approved 46 novel drugs for humans in 2025, fewer than 10 new animal drugs are approved each year across all species, leaving veterinarians with limited treatment options despite validated human science existing for these conditions.
Solution
Familiar bridges the gap between human and veterinary medicine by taking proven human drug candidates—small molecules with validated targets and established safety data—and translating them into novel therapeutics for companion animals. The company's proprietary pipeline prioritizes indications where human science is furthest ahead and veterinary need is greatest, advancing programs only when cross-species work confirms their validity. Familiar also develops companion diagnostics designed to identify patients most likely to benefit from treatment and to monitor response, closing the loop between detection and care. By focusing on small molecules, the company ensures therapies are scalable, manufacturable, and deliverable through every veterinary clinic, not just specialty centers, maximizing access for pets everywhere.
Target Audience
Primary customers are veterinary clinics, companion animal hospitals, and veterinarians seeking modern therapeutic options and diagnostic tools for pets with cancer, autoimmune, and metabolic diseases.
Features
- Translational pipeline that repurposes human-approved small molecules with validated targets and established safety profiles for veterinary use
- 13 active drug development programs spanning cancers, autoimmune conditions, and metabolic diseases
- Lead candidate FAM-010, a new form of doxorubicin engineered to deliver more medicine to tumors while reducing exposure to healthy tissue, currently in a pilot clinical study for dogs with hemangiosarcoma of the spleen
- Point-of-care companion diagnostics that identify patients most likely to benefit from treatment and monitor therapeutic response
- Cross-species biology approach that enables insights to flow bidirectionally between human and veterinary medicine
- Small-molecule focus ensuring scalability, manufacturability, and delivery through any veterinary clinic
- Clinical trial network enabling veterinarians to shape development priorities and access emerging therapies